Italy-based Philogen, a privately-owned biotechnology company, yesterday announced three new partnering deals.
The companies are US biotech major Celgene (Nasdaq: CELG), Johnson & Johnson’s (NYSE: JNJ) pharma unit Janssen and Switzerland’s Novartis (NOVN: VX). Philogen disclosed no financial terms for the deals, and provided only sketchy details of their focus.
However, Philogen did say that collaboration and licensing agreements with Celgene and Novartis will both focus on the discovery and development of a new class of immunomodulatory therapeutics, while, the partnership with Janssen will seek to discover new small molecule-based therapeutics using novel lead-generation technologies developed by Philogen's Philochem subsidiary. The latter collaboration was facilitated by Johnson & Johnson Innovation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze